摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tetraphenylimidothioxodiphosphinic acid potassium salt | 17162-84-4

中文名称
——
中文别名
——
英文名称
tetraphenylimidothioxodiphosphinic acid potassium salt
英文别名
N-(Diphenyl-thiophosphinyl)-imido-diphenyl-phosphinsaeure-K-Salz;potassium;diphenylphosphorylimino-diphenyl-sulfido-λ5-phosphane
tetraphenylimidothioxodiphosphinic acid potassium salt化学式
CAS
17162-84-4
化学式
C24H20NOP2S*K
mdl
——
分子量
471.541
InChiKey
YHUQJJTVMDWAMC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.16
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Late transition-metal complexes of [Ph2P(O)NP(E)Ph2]- (E=S or Se) with a P,N-hybrid ligand: synthesis and structure
    作者:Alexandra M. Z. Slawin、Martin B. Smith
    DOI:10.1039/a902738f
    日期:——
    N)][Ph2P(O)NP(E)Ph2] were obtained in excellent yields (>90%). Reaction of [Pd(Ph2PC6H4NH2-P,N)2]Cl2 with K[Ph2P(O)NP(S)Ph2] (1:2 molar ratio) gave a mixture of three products identified by 31P-1H} NMR as [Pd(Ph2PC6H4NH-P,N) (Ph2PC6H4NH2-P,N)][Ph2P(O)NP(S)Ph2], [Pd(Ph2PC6H4NH-P,N)Ph2P(O)NP(S)Ph2-O,S}] (P trans to O) and Ph2PC6H4NH2. Alternatively the neutral compound [Pd(Ph2PC6H4NH-P,N)Ph2P(O)NP(S)Ph2-O
    非对称配体[Ph 2 P(O)NP(E)Ph 2 ] -(E = S或Se)采用一系列连接模式(O,E螯合物,E单齿和作为非配位阴离子)与选定的后期过渡属叔膦配合物反应。因此,用甲醇中的K [Ph 2 P(O)NP(E)Ph 2 ]处理顺式-[PtCl 2(PPh 3)2 ]可获得预期的六元O,E-螯合物[Pt(PPh 3)2 Ph 2 P(O)NP(E)Ph 2 - O,E }] +分离为其六氟磷酸盐。当[(PH 2 PC 6 H ^ 4 NH 2 - P,Ñ)2 ]2被允许在类似条件下进行反应的单阳离子的混合物[(PH 2 PC 6 H ^ 4 NH- P,Ñ)(PH 2 PC 6 ħ 4 NH 2 - P,ñ)] [PH 2 P(O)NP(E)PH 2 ]以优良产率(> 90%)获得。[Pd(Ph 2具有K [Ph 2 P(O)NP(S)Ph 2 ](摩尔比为1:2)的PC
  • Organolead(IV) derivatives of oxophosphorus ligands.
    作者:Richard A. Varga、John E. Drake、Cristian Silvestru
    DOI:10.1016/s0022-328x(03)00229-8
    日期:2003.5
    Ph2Pb[(OPPh2)2N]2 (1), Ph2Pb[(OPPh2)(SPPh2)N]2 (2), Me3Pb[(OPPh2)2N] (3) and Ph3Pb[(OPPh2)(SPPh2)N] (4). Attempts to grow crystals of Me3Pb[(OPPh2)2N] (3) led to isolation of Me2Pb[(OPPh2)2N]2 (5), as a result of decomposition. Me3Pb(O2PPh2) (6) was obtained from Me3PbCl and Na(O2PPh2). The compounds were characterized by IR and multinuclear NMR spectroscopy. The molecular structures of 1, 5 and 6 were
    R 4- n PbCl n与Na [(OPPh 2)2 N]或K [(OPPh 2)(SPPh 2)N]的反应可分离出Ph 2 Pb [(OPPh 2)2 N] 2(1) ,Ph 2 Pb [(OPPh 2)(SPPh 2)N] 2(2),Me 3 Pb [(OPPh 2)2 N](3)和Ph 3 Pb [(OPPh 2)(SPPh 2)N](第四名)。试图生长Me 3 Pb [(OPPh 2)2 N](3)晶体的结果是,由于分解,导致Me 2 Pb [(OPPh 2)2 N] 2(5)分离。从Me 3 PbCl和Na(O 2 PPh 2)获得Me 3 Pb(O 2 PPh 2)(6)。通过IR和多核NMR光谱对化合物进行表征。的分子结构1,5和6通过单晶X射线衍射确定。5的晶体在晶胞中包含两个独立的分子。在这两种化合物中,亚二膦配体均充当单属双连接单元,从而形成具有扭曲的舟形构型的六元PbO
  • Phenylmercury(II) derivatives of tetraorganodichalcogenoimidodiphosphorus acids. Crystal and molecular structure of [PhHg{(OPR2)(SPPh2)N}]2 (R=Me, Ph)
    作者:Oana Bumbu、Anca Silvestru、Cristian Silvestru、John E Drake、Michael B Hursthouse、Mark E Light
    DOI:10.1016/j.jorganchem.2003.07.016
    日期:2003.12
    PhHgCl or PhHgAc and M[(XPR2)(YPR′2)N] (M=Na, K; X, Y=O, S; R, R′=Me, Ph, OEt), in 1:1 molar ratio, have been investigated. PhHg[(XPR2)(YPR′2)N] derivatives were isolated as microcrystalline powders and were characterised using IR and NMR (1H, 13C and 31P) spectroscopy and mass spectrometry. The molecular structure of PhHg[(OPR2)(SPPh2)N] [R=Me (1), Ph (2)] was investigated by X-ray diffraction. In the
    PhHgCl或PhHgAc和M之间的反应[(XPR 2)(YPR' 2)N](M =; X,Y = O,S; R,R'= Me中,pH值,OET),在1:已经研究了1摩尔比。PhHg [(XPR 2)(YPR' 2)N]的衍生物,分离微晶粉末和使用IR和NMR(进行了表征1 H,13 C和31 P)谱和质谱测定。通过X射线衍射研究了PhHg [(OPR 2)(SPPh 2)N] [R = Me(1),Ph(2)]的分子结构。在单体单元中,PhHg [(OPR 2)(SPPh 2)N],原子形成主键与基的配体原子[柱(1)-S(1)2.405(1)1,2.398(2)一种2 ]。这些主键与预期线性布置显著偏离[C(1)-Hg(1)-S(1)166.4(2)°,1,165.0(2)°,2 ]。这两种化合物显示出通过在晶体中二聚体协会小号,ö -bridging有机配体[柱(1)-O(1)2
  • Synthesis and characterisation of E,O-mixed donor (E=P, S or Se) ligand complexes of palladium(II) and platinum(II)
    作者:Martin B Smith*、Alexandra M.Z Slawin*
    DOI:10.1016/s0020-1693(99)00493-4
    日期:2000.3
    [Pd(μ-Cl)(C 12 H 9 N 2 )} 2 ] with the unsymmetrical anions [Ph 2 P(E)NP(O)Ph 2 ] − (E=S or Se) gave the square–planar complexes [Pd(C 12 H 9 N 2 )Ph 2 P(E)NP(O)Ph 2 - E , O }] exclusively as one isomer (E trans to N). In a similar manner the new metal(II) compounds [PtClPh 2 P(E)NP(O)Ph 2 - E , O }(PMe 2 Ph)] (E trans to Cl) and [Pd(C 9 H 15 O)Ph 2 P(E)NP(O)Ph 2 - E , O }] (E trans to olefin double bond)
    摘要具有杂配体Ph 2 PNHP(O)Ph 2,[Ph 2 PNP(O)Ph 2]-或[Ph 2 P(E)NP(O)Ph 2的新型(II)和(II)配合物]-(E = S或Se)已经准备好并进行了表征。因此,环属化二聚体[Pd(μ-Cl)(C〜N)} 2] [C〜N = C 12 H 9 N 2或C 13 H 8 N]与Ph 2 PNHP(O)Ph 2的反应得到单核化合物[PdCl(C〜N)Ph 2 PNHP(O)Ph 2-P}]。化物提取或胺去质子化得到[Pd(C〜N)Ph 2 PNHP(O)Ph 2-P,O}] [BF 4]或[Pd(C〜N)Ph 2 PNP(O)Ph 2-P,O}]分别带有中性或阴离子P,O螯合配体。[Pd(μ-Cl)(C 9 H 12 N)} 2与Ph 2 PNHP(O)Ph 2在CDCl 3溶液中的反应产生了已知的,相当不稳定的化合物[PdCl(C
  • Synthesis and conformational studies of palladium(II) complexes containing [Ph2P(O)NP(E)Ph2]− (E=S or Se)
    作者:Alexandra M.Z. Slawin、Martin B. Smith、J.Derek Woollins
    DOI:10.1016/s0277-5387(98)00253-8
    日期:1998.11
    =PPh 3 ; 2PR 3 =Ph 2 PCH 2 CH 2 PPh 2 or cis -Ph 2 PCH=CHPPh 2 ] with either I (or II) in thf or CH 3 OH gave [PdPh 2 P(O)NP(E)Ph 2 - O,E }(bipy)]PF 6 , [PdPh 2 P(O)NP(E)Ph 2 - O , E }(L–L)], [PdPh 2 P(O)NP(E)Ph 2 - O , E }Cl(PMe 2 Ph)] or [PdPh 2 P(O)NP(E)Ph 2 - O , E } (PR 3 ) 2 ]PF 6 in good yields. All compounds described have been characterised by a combination of multinuclear NMR [31 P1 H} and
    配体[Ph 2 P(O)NP(E)Ph 2]-(E = SI; E = Se II)可以很容易地与一系列(II)起始原料络合,从而提供新的六元Pd–O– P–N–P–E palladacycles。因此,化物络合物[PdCl 2(bipy)](bipy = 2,2'-bipyridine),[Pd(μ-Cl)(L–L)} 2](HL–L = C 9 H 13 N或C 12 H 13 N),[Pd(μ-Cl)Cl(PMe 2 Ph)} 2]或[PdCl 2(PR 3)2] [PR 3 = PPh 3;2PR 3 = Ph 2 PCH 2 CH 2 PPh 2或顺式-Ph 2 PCH = CHPPh 2],其中I(或II)在thf或CH 3 OH中,得到[Pd Ph 2 P(O)NP(E)Ph 2 -O,E}(bipy)] PF 6,[Pd Ph 2 P(O)NP(E)Ph 2-O,E}(L–L)],[Pd
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫